scholarly journals Blockade of interleukin-6 receptor in the periphery promotes rapid and sustained antidepressant actions: a possible role of gut–microbiota–brain axis

2017 ◽  
Vol 7 (5) ◽  
pp. e1138-e1138 ◽  
Author(s):  
J-c Zhang ◽  
W Yao ◽  
C Dong ◽  
C Yang ◽  
Q Ren ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Interleukin 6 ◽  
Interleukin 6 Receptor

scholarly journals Inducible microRNA-590-5p inhibits host antiviral response by targeting the soluble interleukin-6 (IL6) receptor

2018 ◽  
Vol 293 (47) ◽  
pp. 18168-18179 ◽  
Author(s):  
Yaqin Zhou ◽  
Zhangchuan Xia ◽  
Zhikui Cheng ◽  
Gang Xu ◽  
Xiaodan Yang ◽  
...  
Keyword(s):  
Viral Infection ◽  
Interleukin 6 ◽  
Underlying Mechanism ◽  
Antiviral Response ◽  
Type I ◽  
Interleukin 6 Receptor ◽  
Important Regulator ◽  
Membrane Bound ◽  
Host Antiviral Response

MicroRNA (miR)-590-5p has been identified as an important regulator of some signaling pathways such as cell proliferation and tumorigenesis. However, little is known about its role during viral infection. Here, we report that miR-590-5p was significantly induced by various viruses and effectively potentiated virus replication in different viral infection systems. Furthermore, miR-590-5p substantially attenuated the virus-induced expression of type I and type III interferons (IFNs) and inflammatory cytokines, resulting in impaired downstream antiviral signaling. Interleukin-6 receptor (IL6R) was identified as a target of miR-590-5p. Interestingly, the role of miR-590-5p in virus-triggered signaling was abolished in IL6R knockout cells, and this could be rescued by restoring the expression of the soluble IL6R (sIL6R) but not the membrane-bound IL6R (mIL6R), suggesting that sIL6R is indispensable for miR-590-5p in modulating the host antiviral response. Furthermore, miR-590-5p down-regulated endogenous sIL6R and mIL6R expression through a translational repression mechanism. These findings thus uncover a previously uncharacterized role and the underlying mechanism of miR-590-5p in the innate immune response to viral infection.

The role of soluble interleukin-6 receptor in inflammatory diseases

2005 ◽  
Vol 98 (1) ◽  
pp. 171
Author(s):  
Marcello Maggio ◽  
Shehzad Basaria ◽  
Gian Paolo Ceda ◽  
Graziano Ceresini ◽  
Giorgio Valenti ◽  
...  
Keyword(s):  
Interleukin 6 ◽  
Inflammatory Diseases ◽  
Interleukin 6 Receptor

scholarly journals A Potential Role of IL-6/IL-6R in the Development and Management of Colon Cancer

Membranes ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. 312
Author(s):  
Mimmo Turano ◽  
Francesca Cammarota ◽  
Francesca Duraturo ◽  
Paola Izzo ◽  
Marina De Rosa
Keyword(s):  
Colorectal Cancer ◽  
Colon Cancer ◽  
Cancer Progression ◽  
Interleukin 6 ◽  
Potential Role ◽  
Target Cells ◽  
Sporadic Colorectal Cancer ◽  
Colon Cancer Progression ◽  
Interleukin 6 Receptor

Colorectal cancer (CRC) is the third most frequent cancer worldwide and the second greatest cause of cancer deaths. About 75% of all CRCs are sporadic cancers and arise following somatic mutations, while about 10% are hereditary cancers caused by germline mutations in specific genes. Several factors, such as growth factors, cytokines, and genetic or epigenetic alterations in specific oncogenes or tumor-suppressor genes, play a role during the adenoma–carcinoma sequence. Recent studies have reported an increase in interleukin-6 (IL-6) and soluble interleukin-6 receptor (sIL-6R) levels in the sera of patients affected by colon cancer that correlate with the tumor size, suggesting a potential role for IL-6 in colon cancer progression. IL-6 is a pleiotropic cytokine showing both pro- and anti-inflammatory roles. Two different types of IL-6 signaling are known. Classic IL-6 signaling involves the binding of IL-6 to its membrane receptor on the surfaces of target cells; alternatively, IL-6 binds to sIL-6R in a process called IL-6 trans-signaling. The activation of IL-6 trans-signaling by metalloproteinases has been described during colon cancer progression and metastasis, involving a shift from membrane-bound interleukin-6 receptor (IL-6R) expression on the tumor cell surface toward the release of soluble IL-6R. In this review, we aim to shed light on the role of IL-6 signaling pathway alterations in sporadic colorectal cancer and the development of familial polyposis syndrome. Furthermore, we evaluate the possible roles of IL-6 and IL-6R as biomarkers useful in disease follow-up and as potential targets for therapy, such as monoclonal antibodies against IL-6 or IL-6R, or a food-based approach against IL-6.

Castleman’s disease and arterial thrombosis: result of excessively elevated interleukin-6 plasma level?

VASA ◽  
2012 ◽  
Vol 41 (2) ◽  
pp. 145-148 ◽  
Author(s):  
Schumacher ◽  
Jacomella ◽  
Stüssi ◽  
Amann-Vesti ◽  
Corti ◽  
...  
Keyword(s):  
Plasma Level ◽  
Interleukin 6 ◽  
Arterial Thrombosis ◽  
Limb Ischemia ◽  
Thrombus Aspiration ◽  
Interleukin 6 Receptor ◽  
Morbus Castleman ◽  
Plasma Cell Disorder ◽  
Cell Disorder

Morbus Castleman is a benign non-clonal lymphoproliverative disorder. Immunomodulatory and antiproliferative drugs are used to treat this plasma cell disorder. We report the case of a 46-year old female patient with multicentric Castleman’s disease and limb ischemia. Thrombotic occlusions of the popliteal and tibioperoneal arteries were treated by percutaneous thrombus aspiration. We discuss the role of increased interleukin-6 plasma levels during therapy with Tocilizumab, an antibody to interleukin-6 receptor, as a potential cause for arterial thrombosis.

Role of Soluble Interleukin-6 Receptor With Interleukin-6 in Human Hematopoiesis

Hematology ◽  
1997 ◽  
Vol 2 (2) ◽  
pp. 143-149
Author(s):  
Kohichiro Tsuji ◽  
Tatsutoshi Nakahata
Keyword(s):  
Interleukin 6 ◽  
Interleukin 6 Receptor
Sign in / Sign up

Export Citation Format

Share Document